Results
1 -
10 of
67LeWitt Peter A., Guttman M., Tetrud James W., Tuite Paul J., Mori Akihisa, Chaikin Philip, Sussman Neil M..
Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005), Annals of Neurology, 2008 Computational studies of the binding modes of A2A adenosine receptor antagonists, Amino Acids Treatment of Parkinsonu2019s Disease: Whatu2019s in the Non-dopaminergic Pipeline?, Neurotherapeutics Adenosine A2A Receptor Antagonists in L-DOPA-Induced Motor Fluctuations, The Adenosinergic System Dopamine/Adenosine Interactions Related to Tremor in Animal Models of Parkinsonism, The Adenosinergic System Effects of Adenosine Receptor Antagonists on the In Vivo LPS-Induced Inflammation Model of Parkinsonu2019s Disease, Neurotoxicity Research Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson?s Disease, Adenosine The Role of Adenosine in the Ventral Striatal Circuits Regulating Behavioral Activation and Effort-Related Decision Making: Importance for Normal and Pathological Aspects of Motivation, Adenosine